InvestLog
CMMB Chemomab Therapeutics Ltd. logo

CMMB Chemomab Therapeutics Ltd.

Healthcare
$2.02+9.37%ClosedMarket Cap: $12.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.51

P/S

0.00

EV/EBITDA

-0.82

DCF Value

$1.56

FCF Yield

-90.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-67.8%

ROA

-63.1%

ROIC

-74.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-1.8M$—
Q4 null$0.00$-1.9M$—
FY null$0.00$-9.0M$—
Q3 null$0.00$-1.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
OppenheimerOutperform
2025-08-27

Trading Activity

Insider Trades

View All
Mor George Adidirector, officer: Chief Executive Officer
SellFri Apr 10
Mor George Adidirector, officer: Chief Executive Officer
SellFri Apr 10
Mor George Adidirector, officer: Chief Executive Officer
SellFri Apr 10
Mor George Adidirector, officer: Chief Executive Officer
SellFri Apr 10
Darvish Nissimdirector
SellFri Apr 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

—

Beta

0.51

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Peers

BIVI logoBIVICANF logoCANFCERO logoCEROELAB logoELABGLMD logoGLMDINM logoINMKZIA logoKZIAOCEA logoOCEATOVX logoTOVXXRTX logoXRTX